Eflornithine + Sulindac for Colorectal Cancer Prevention
(PACES Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether a combination of two drugs, eflornithine (also known as Vaniqa, Iwilfin, Ornidyl, α-difluoromethylornithine, or DFMO) and sulindac, can prevent new adenomas (a type of tumor) and additional colorectal cancers in individuals previously treated for early-stage colon or rectal cancer. The trial includes different groups where participants may receive both drugs, one of the drugs, or a placebo (a non-active substance) to compare effectiveness. Individuals who have undergone surgery for Stage 0-III colon or rectal cancer and show no current signs of cancer might be suitable for this study. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking cancer prevention treatments.
Will I have to stop taking my current medications?
The trial requires that you do not take certain medications regularly, such as intravenous corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), or anticoagulants. You can use NSAIDs for up to 10 days per month, and aspirin is limited to a maximum dose of 100 mg per day or two 325 mg tablets per week. Inhaled steroids are allowed.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that using eflornithine with a non-steroidal anti-inflammatory drug (NSAID) like sulindac is safe and effective in preventing colorectal adenomas, which are polyps that can lead to cancer. Studies have found that this combination therapy reduces the chance of these polyps returning in individuals with a history of advanced colorectal tumors.
Sulindac, an NSAID, is known for its role in preventing colorectal cancer. It has undergone testing in human clinical trials and is considered safe for treating colorectal polyps. However, its efficacy and safety as a standalone treatment for this purpose remain unclear.
Past studies indicated that using eflornithine and sulindac together did not significantly slow disease progression compared to using either drug alone, but both drugs have been well-tolerated in clinical settings. Participants can therefore expect a reasonable level of safety if they join a trial involving these treatments.12345Why are researchers excited about this trial's treatments?
Researchers are excited about using eflornithine and sulindac for colorectal cancer prevention because these drugs offer a unique approach. Unlike standard treatments, which often focus on surgical removal or chemotherapy, eflornithine and sulindac work by interfering with specific biochemical pathways that promote cancer cell growth. Eflornithine inhibits an enzyme called ornithine decarboxylase, which is crucial for cell division, while sulindac reduces inflammation and related cancer risk. This combination could potentially prevent cancer before it even starts, offering a promising strategy for high-risk individuals.
What evidence suggests that this trial's treatments could be effective for colorectal cancer prevention?
This trial will evaluate the effectiveness of eflornithine and sulindac, both separately and in combination, for colorectal cancer prevention. Studies have shown that using eflornithine with sulindac can significantly reduce the recurrence of adenomatous polyps, which are colon growths that can become cancerous. This combination treatment has successfully lowered the number of these polyps in individuals with a history of advanced colorectal tumors. Research also shows that sulindac alone can help prevent tumors, as it is a non-steroidal anti-inflammatory drug (NSAID). While eflornithine alone has produced mixed results, its combination with sulindac appears promising for reducing cancer risks. Overall, evidence suggests that eflornithine and sulindac together may help prevent colorectal cancer.12467
Who Is on the Research Team?
Jason A. Zell
Principal Investigator
University of California, Irvine
Are You a Good Fit for This Trial?
This trial is for adults who've had Stage 0-III colon or rectal cancer and completed surgery a year ago, with no current evidence of disease. They must have finished chemo and radiation at least 30 days prior, be able to swallow pills, not take certain drugs regularly (like NSAIDs), and have stable vital signs. Pregnant women or those with high cardiovascular risks are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive eflornithine and sulindac or corresponding placebos daily for 3 years
Follow-up
Participants are monitored for safety and effectiveness after treatment, with analyses of colorectal event rates through year 8
What Are the Treatments Tested in This Trial?
Interventions
- Eflornithine
- Sulindac
Trial Overview
The study tests if eflornithine combined with sulindac can prevent the return of adenomas or colorectal cancers in patients previously treated for these conditions. Participants will receive either both drugs, one drug plus a placebo, or double placebos over three years.
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
Placebo Group
Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac placebo one tablet PO daily for 3 years.
Eflornithine placebo 2 tablets, PO, daily for 3 years. Sulindac placebo, 1 tablet, PO, daily for 3 years.
Eflornithine is already approved in European Union, United States for the following indications:
- Hirsutism
- African trypanosomiasis
- Hirsutism
- High-risk neuroblastoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Southwest Oncology Group
Lead Sponsor
SWOG Cancer Research Network
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
Cancer Prevention Pharmaceuticals, Inc.
Industry Sponsor
Published Research Related to This Trial
Citations
Eflornithine for chemoprevention in the high-risk population ...
Objectives. To evaluate the efficacy of Difluoromethylornithine (DFMO) chemoprevention in the high-risk population for colorectal cancer (CRC).
Eflornithine for chemoprevention in the high-risk population ...
The combination therapy of DFMO effectively diminishes the occurrence of recurrent adenomas in patients with a history of advanced colorectal tumors.
5 DFMO: Targeted risk reduction therapy for colorectal ...
Human trials of DFMO alone have shown mixed results in cancer chemoprevention. Topical DFMO reduced by one-quarter the number of pre-malignant actinic keratoses ...
eflornithine (dfmo) tablets to reduce the risk of
... DFMO in adult patients at risk of colorectal cancer, with history of and risk for recurrent adenomas, or at risk of skin cancer were reviewed.
a systematic review and meta-analysis with trial sequential ...
PDF | Objectives To evaluate the efficacy of Difluoromethylornithine (DFMO) chemoprevention in the high-risk population for colorectal cancer.
DFMO: targeted risk reduction therapy for colorectal ...
DFMO in combination with a non-steroidal anti-inflammatory drug (NSAID) has been shown to be safe and effective in chemoprevention of colorectal adenomas.
Eflornithine plus Sulindac for Prevention of Progression in ...
The incidence of disease progression was not significantly lower with the combination of eflornithine and sulindac than with either drug alone.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.